Comments
Loading...

Sage Therapeutics Analyst Ratings

SAGENASDAQ
Logo brought to you by Benzinga Data
$6.53
-0.08-1.21%
At close: -
$6.66
0.131.99%
After Hours: 4:44 PM EDT
Consensus Rating1
Neutral
Highest Price Target1
$26.00
Lowest Price Target1
$4.00
Consensus Price Target1
$11.55

Sage Therapeutics Analyst Ratings and Price Targets | NASDAQ:SAGE | Benzinga

Sage Therapeutics Inc has a consensus price target of $11.55 based on the ratings of 22 analysts. The high is $26 issued by Piper Sandler on October 30, 2024. The low is $4 issued by RBC Capital on November 21, 2024. The 3 most-recent analyst ratings were released by Scotiabank, Wedbush, and Canaccord Genuity on February 12, 2025, respectively. With an average price target of $8.67 between Scotiabank, Wedbush, and Canaccord Genuity, there's an implied 30.13% upside for Sage Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Dec 24
1
Jan
2
Feb
0
0
0
0
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.4
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Scotiabank
Wedbush
Canaccord Genuity
HC Wainwright & Co.
Piper Sandler

1calculated from analyst ratings

Analyst Ratings for Sage Therapeutics

Buy NowGet Alert
04/30/2025Buy Now—Needham
Ami Fadia56%
—ReiteratesHold → HoldGet Alert
04/25/2025Buy Now—Needham
Ami Fadia56%
—ReiteratesHold → HoldGet Alert
02/12/2025Buy Now80.18%Scotiabank
George Farmer39%
$14 → $12MaintainsSector OutperformGet Alert
02/12/2025Buy Now-9.91%Wedbush
Laura Chico46%
$6 → $6ReiteratesNeutral → NeutralGet Alert
02/12/2025Buy Now20.12%Canaccord Genuity
Sumant Kulkarni42%
$9 → $8MaintainsHoldGet Alert
02/12/2025Buy Now80.18%HC Wainwright & Co.
Douglas Tsao51%
$14 → $12ReiteratesNeutral → NeutralGet Alert
02/12/2025Buy Now—Needham
Ami Fadia56%
—ReiteratesHold → HoldGet Alert
01/02/2025Buy Now35.14%Piper Sandler
David Amsellem77%
$26 → $9MaintainsOverweightGet Alert
12/16/2024Buy Now-9.91%Stifel
Paul Matteis44%
$10 → $6MaintainsHoldGet Alert
11/21/2024Buy Now35.14%TD Cowen
Ritu Baral34%
$10 → $9MaintainsHoldGet Alert
11/21/2024Buy Now-39.94%RBC Capital
Brian Abrahams49%
$4 → $4UpgradeUnderperform → Sector PerformGet Alert
11/20/2024Buy Now110.21%HC Wainwright & Co.
Douglas Tsao51%
$14 → $14ReiteratesNeutral → NeutralGet Alert
11/20/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
10/30/2024Buy Now110.21%Scotiabank
George Farmer39%
$17 → $14MaintainsSector OutperformGet Alert
10/30/2024Buy Now290.39%Piper Sandler
Yasmeen Rahimi54%
$52 → $26ReiteratesOverweight → OverweightGet Alert
10/30/2024Buy Now20.12%Oppenheimer
Jay Olson60%
$9 → $8MaintainsPerformGet Alert
10/30/2024Buy Now20.12%Truist Securities
Joon Lee76%
$13 → $8MaintainsHoldGet Alert
10/30/2024Buy Now110.21%HC Wainwright & Co.
Douglas Tsao51%
$25 → $14MaintainsNeutralGet Alert
10/30/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
10/17/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
10/10/2024Buy Now—Raymond James
Danielle Brill44%
—Reinstates → Market PerformGet Alert
10/09/2024Buy Now-9.91%B of A Securities
Tazeen Ahmad55%
$11 → $6MaintainsUnderperformGet Alert
10/09/2024Buy Now20.12%Wedbush
Laura Chico46%
$9 → $8MaintainsNeutralGet Alert
10/09/2024Buy Now35.14%Baird
Joel Beatty67%
$13 → $9MaintainsNeutralGet Alert
10/09/2024Buy Now275.38%HC Wainwright & Co.
Douglas Tsao51%
$25 → $25ReiteratesNeutral → NeutralGet Alert
10/08/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
10/04/2024Buy Now-39.94%RBC Capital
Brian Abrahams49%
$10 → $4DowngradeSector Perform → UnderperformGet Alert
08/14/2024Buy Now95.2%Truist Securities
Joon Lee76%
$18 → $13MaintainsHoldGet Alert
08/06/2024Buy Now50.15%JP Morgan
Anupam Rama57%
$12 → $10MaintainsNeutralGet Alert
08/02/2024Buy Now275.38%HC Wainwright & Co.
Douglas Tsao51%
$25 → $25ReiteratesNeutral → NeutralGet Alert
08/01/2024Buy Now680.78%Piper Sandler
Yasmeen Rahimi54%
$70 → $52MaintainsOverweightGet Alert
08/01/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
07/30/2024Buy Now50.15%TD Cowen
Ritu Baral34%
$16 → $10DowngradeBuy → HoldGet Alert
07/26/2024Buy Now65.17%Goldman Sachs
Salveen Richter54%
$19 → $11MaintainsNeutralGet Alert
07/25/2024Buy Now155.26%Scotiabank
George Farmer39%
$19 → $17MaintainsSector OutperformGet Alert
07/25/2024Buy Now80.18%JP Morgan
Anupam Rama57%
$18 → $12DowngradeOverweight → NeutralGet Alert
07/25/2024Buy Now95.2%Baird
Joel Beatty67%
$15 → $13MaintainsNeutralGet Alert
07/25/2024Buy Now275.38%HC Wainwright & Co.
Douglas Tsao51%
$25 → $25ReiteratesNeutral → NeutralGet Alert
07/24/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
07/19/2024Buy Now140.24%Mizuho
Uy Ear64%
$18 → $16MaintainsNeutralGet Alert
07/12/2024Buy Now170.27%JP Morgan
Anupam Rama57%
$23 → $18MaintainsOverweightGet Alert
07/02/2024Buy Now275.38%HC Wainwright & Co.
Douglas Tsao51%
$25 → $25ReiteratesNeutral → NeutralGet Alert
06/28/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
06/20/2024Buy Now245.35%JP Morgan
Anupam Rama57%
$28 → $23MaintainsOverweightGet Alert
06/12/2024Buy Now275.38%HC Wainwright & Co.
Douglas Tsao51%
$25 → $25ReiteratesNeutral → NeutralGet Alert
06/11/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
06/11/2024Buy Now125.23%Baird
Joel Beatty67%
$15 → $15MaintainsNeutralGet Alert
05/29/2024Buy Now20.12%Citigroup
David Hoang42%
→ $8Initiates → SellGet Alert
05/29/2024Buy Now125.23%Baird
Joel Beatty67%
→ $15Initiates → NeutralGet Alert
05/01/2024Buy Now320.42%JP Morgan
Anupam Rama57%
$29 → $28MaintainsOverweightGet Alert
04/26/2024Buy Now275.38%HC Wainwright & Co.
Douglas Tsao51%
$28 → $25MaintainsNeutralGet Alert
04/26/2024Buy Now185.29%Goldman Sachs
Salveen Richter54%
$28 → $19MaintainsNeutralGet Alert
04/26/2024Buy Now125.23%RBC Capital
Brian Abrahams49%
$26 → $15MaintainsSector PerformGet Alert
04/26/2024Buy Now170.27%Truist Securities
Joon Lee76%
$22 → $18MaintainsHoldGet Alert
04/26/2024Buy Now170.27%Mizuho
Uy Ear64%
$20 → $18MaintainsNeutralGet Alert
04/26/2024Buy Now155.26%Canaccord Genuity
Sumant Kulkarni42%
$21 → $17MaintainsHoldGet Alert
04/26/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
04/25/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
04/18/2024Buy Now185.29%Scotiabank
George Farmer39%
$34 → $19MaintainsSector OutperformGet Alert
04/18/2024Buy Now155.26%Oppenheimer
Jay Olson60%
$25 → $17MaintainsPerformGet Alert
04/18/2024Buy Now140.24%TD Cowen
Ritu Baral34%
$30 → $16MaintainsBuyGet Alert
04/18/2024Buy Now—Needham
Ami Fadia56%
—Reiterates → HoldGet Alert
04/17/2024Buy Now320.42%HC Wainwright & Co.
Douglas Tsao51%
$28 → $28ReiteratesNeutral → NeutralGet Alert
04/17/2024Buy Now260.36%Wedbush
Laura Chico46%
$24 → $24ReiteratesNeutral → NeutralGet Alert
04/17/2024Buy Now110.21%B of A Securities
Tazeen Ahmad55%
$24 → $14DowngradeNeutral → UnderperformGet Alert
03/26/2024Buy Now335.44%JP Morgan
Anupam Rama57%
$24 → $29MaintainsOverweightGet Alert
03/11/2024Buy Now290.39%RBC Capital
Brian Abrahams49%
$26 → $26ReiteratesSector Perform → Sector PerformGet Alert
02/28/2024Buy Now230.33%Morgan Stanley
Vikram Purohit37%
$20 → $22MaintainsEqual-WeightGet Alert
02/15/2024Buy Now320.42%HC Wainwright & Co.
Douglas Tsao51%
$25 → $28MaintainsNeutralGet Alert
02/15/2024Buy Now290.39%RBC Capital
Brian Abrahams49%
$21 → $26MaintainsSector PerformGet Alert
12/18/2023Buy Now200.3%Stifel
Paul Matteis44%
$22 → $20MaintainsHoldGet Alert
12/12/2023Buy Now215.32%Deutsche Bank
Neena Bitritto-Garg58%
→ $21Initiates → HoldGet Alert
11/08/2023Buy Now215.32%RBC Capital
Brian Abrahams49%
$22 → $21MaintainsSector PerformGet Alert
11/08/2023Buy Now230.33%Wedbush
Laura Chico46%
$21 → $22MaintainsNeutralGet Alert
10/13/2023Buy Now275.38%Goldman Sachs
Salveen Richter54%
$22 → $25MaintainsNeutralGet Alert
09/08/2023Buy Now260.36%B of A Securities
Tazeen Ahmad55%
$25 → $24MaintainsNeutralGet Alert
09/07/2023Buy Now200.3%Mizuho
Vamil Divan72%
$19 → $20MaintainsNeutralGet Alert
09/07/2023Buy Now230.33%RBC Capital
Brian Abrahams49%
$25 → $22MaintainsSector PerformGet Alert
08/09/2023Buy Now230.33%Goldman Sachs
Salveen Richter54%
$75 → $22MaintainsNeutralGet Alert
08/09/2023Buy Now200.3%Morgan Stanley
Vikram Purohit37%
$49 → $20MaintainsEqual-WeightGet Alert
08/08/2023Buy Now320.42%TD Cowen
Ritu Baral34%
$105 → $28MaintainsOutperformGet Alert
08/08/2023Buy Now200.3%Oppenheimer
Jay Olson60%
$24 → $20MaintainsPerformGet Alert
08/08/2023Buy Now275.38%RBC Capital
Brian Abrahams49%
→ $25ReiteratesSector Perform → Sector PerformGet Alert
08/08/2023Buy Now200.3%Truist Securities
Joon Lee76%
$40 → $20MaintainsHoldGet Alert
08/08/2023Buy Now185.29%Mizuho
Vamil Divan72%
$45 → $19MaintainsNeutralGet Alert
08/08/2023Buy Now230.33%Goldman Sachs
Salveen Richter54%
→ $22DowngradeBuy → NeutralGet Alert
08/08/2023Buy Now215.32%Canaccord Genuity
Sumant Kulkarni42%
$64 → $21DowngradeBuy → HoldGet Alert
08/08/2023Buy Now—Needham
Ami Fadia56%
—DowngradeBuy → HoldGet Alert
08/08/2023Buy Now305.41%HC Wainwright & Co.
Douglas Tsao51%
$50 → $27MaintainsNeutralGet Alert
08/07/2023Buy Now230.33%Stifel
Paul Matteis44%
$60 → $22DowngradeBuy → HoldGet Alert
08/07/2023Buy Now230.33%Wedbush
Laura Chico46%
→ $22DowngradeOutperform → NeutralGet Alert
08/07/2023Buy Now650.75%HC Wainwright & Co.
Douglas Tsao51%
→ $50ReiteratesNeutral → NeutralGet Alert
08/07/2023Buy Now275.38%RBC Capital
Brian Abrahams49%
$71 → $25DowngradeOutperform → Sector PerformGet Alert
08/07/2023Buy Now—Oppenheimer
Jay Olson60%
—DowngradeOutperform → PerformGet Alert
08/07/2023Buy Now951.05%Needham
Ami Fadia56%
→ $70ReiteratesBuy → BuyGet Alert
08/03/2023Buy Now635.74%Morgan Stanley
Vikram Purohit37%
$49 → $49MaintainsEqual-WeightGet Alert
07/27/2023Buy Now815.92%Scotiabank
George Farmer39%
→ $61Initiates → Sector OutperformGet Alert
05/23/2023Buy Now815.92%B of A Securities
Tazeen Ahmad55%
$56 → $61MaintainsBuyGet Alert
05/23/2023Buy Now650.75%HC Wainwright & Co.
Douglas Tsao51%
→ $50ReiteratesNeutral → NeutralGet Alert
05/09/2023Buy Now635.74%Morgan Stanley
Vikram Purohit37%
$50 → $49MaintainsEqual-WeightGet Alert

FAQ

Q

What is the target price for Sage Therapeutics (SAGE) stock?

A

The latest price target for Sage Therapeutics (NASDAQ:SAGE) was reported by Needham on April 30, 2025. The analyst firm set a price target for $0.00 expecting SAGE to fall to within 12 months (a possible -100.00% downside). 49 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Sage Therapeutics (SAGE)?

A

The latest analyst rating for Sage Therapeutics (NASDAQ:SAGE) was provided by Needham, and Sage Therapeutics reiterated their hold rating.

Q

When was the last upgrade for Sage Therapeutics (SAGE)?

A

The last upgrade for Sage Therapeutics Inc happened on November 21, 2024 when RBC Capital raised their price target to $4. RBC Capital previously had an underperform for Sage Therapeutics Inc.

Q

When was the last downgrade for Sage Therapeutics (SAGE)?

A

The last downgrade for Sage Therapeutics Inc happened on October 4, 2024 when RBC Capital changed their price target from $10 to $4 for Sage Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Sage Therapeutics (SAGE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sage Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sage Therapeutics was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.

Q

Is the Analyst Rating Sage Therapeutics (SAGE) correct?

A

While ratings are subjective and will change, the latest Sage Therapeutics (SAGE) rating was a reiterated with a price target of $0.00 to $0.00. The current price Sage Therapeutics (SAGE) is trading at is $6.66, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch